Agency IQ

FEBRUARY 15, 2024

CDRH FY2024 Guidance Agenda Clinical application Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma CBER Final By 12/31/24 CBER CY 2024 Guidance Agenda Blood Considerations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method CBER Draft (..)

FDA 40

FDA Science Biosimilars Clinical Trials 40

Agency IQ

JULY 28, 2023

A big nitrosamine deadline approaches : Unless you’ve been hiding under a rock for the last few years, you’ve probably heard about major issues that the pharmaceutical industry has been having with nitrosamine contamination. But despite the law’s age, it is not yet fully operational.

FDA 40

FDA Science Biosimilars Regulations 40

The Pharma Data

DECEMBER 30, 2020

The companies agreed to the steep price cuts in order to have their drugs made available to the world’s second-largest pharmaceutical market. The company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth $111.2 billion by 2027. billion people, Bloomberg said.

Immune Response 52

Immune Response Vaccine Clinical Trials Treatment 52

Agency IQ

JUNE 16, 2023

Amendments to TSCA in 2016 included several new provisions concerning the assertion and Agency review and treatment of CBI claims. The standards would begin with model year 2027 heavy-duty vehicles, with stringency levels through model year 2030 and beyond.

Regulations 40

Regulations Compliance Production Science 40

The Pharma Data

APRIL 7, 2021

Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory ,” said Hudson. Leveraging R&D efforts to address crucial treatment gaps. The company is also committed to ecodesigning all its new products by 2025.

Vaccine 52

Vaccine Packaging Disease Treatment 52

Drug Target Review

MARCH 20, 2025

This development is not just a significant milestone in drug discovery, but also a potential breakthrough for clinical practice, as it may address a critical gap in current treatments by offering effective stroke prevention with a reduced risk of bleeding. This is one of the major challenges that plagues current treatment of AFib.”

Therapies 52

Therapies Trials Clinical Development FDA 52

The Pharma Data

MAY 4, 2021

and developed Europe following the approvals in 2019 for combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced renal cell carcinoma; as well as. RE47,739 for Ibrance by more than four years until March 2027. In February 2021, Pfizer announced that the U.S.

Vaccine 40

Vaccine Production FDA Clinical Trials 40

Agency IQ

DECEMBER 15, 2023

The allowance or “variance” to the prohibition on the open burning of hazardous waste was established at a time when there were no alternatives to the safe treatment of waste explosives. 7521(a), starting with model year 2027. and tractors (such as day cabs and sleeper cabs on tractor-trailer trucks).

Regulations 40

Regulations Compliance Production Government 40